Treatment strategy for HER2-positive breast cancer.

International Journal of Clinical Oncology
Hirofumi Mukai

Abstract

HER2-positive tumors account for approximately 18-20% of all breast cancers. These tumors tend to be more aggressive than HER2-negative tumors and are associated with a poorer prognosis. HER2 overexpression, as determined by either 3+ immunohistochemical staining for HER2 protein or HER2 gene amplification by fluorescence in situ hybridization, should be used to select patients for anti-HER2 therapy. Trastuzumab-containing regimens as first-line therapy should be recommended to women with HER2-positive metastatic breast cancer. The continuation of trastuzumab plus capecitabine provided a significant clinical benefit compared with capecitabine alone in women who experienced progression during trastuzumab treatment. An adjuvant trastuzumab-containing regimen should be also recommended to all intermediate- or high-risk women with HER2-positive early breast cancer. Cardiac function should be serially monitored during this treatment. Many anti-HER2 drugs against breast cancer are being developed. The basic mechanisms of their action and resistance emergence are being clarified step by step. Over the mid- or long term, clinical trials comparing these drugs will be conducted until drugs that are clinically effective and easy to use in...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A GustersonR Reed
Jan 5, 2000·Breast Cancer Research and Treatment·J M GarciaF Bonilla
Dec 26, 2001·Journal of the National Cancer Institute·Y LuM Pollak
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L SpectorSarah Bacus
Feb 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B AgusGwen Fyfe
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Feb 20, 2007·Current Opinion in Cell Biology·Stevan R Hubbard, W Todd Miller
Apr 19, 2007·Journal of the National Cancer Institute·Maurizio ScaltritiJosé Baselga
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rupert BartschGuenther G Steger
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRichard J Rodeheffer
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy U LinEric P Winer
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry L GomezGeorge W Sledge
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kwok-K WongHoward A Burris
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L BlackwellJoyce O'Shaughnessy

❮ Previous
Next ❯

Citations

Jan 10, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jörgen Carlsson
Jan 22, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiaohong DengAnne-Sofie Schrohl
Aug 13, 2013·International Journal of Cell Biology·Claire JacksonAlison Tyson-Capper
May 24, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Methvin IsaacJan Jongstra
Jan 22, 2013·Veterinary Dermatology·Cheryl A London
May 7, 2015·Cell Cycle·Yingjia Ni, Siyuan Zhang
Oct 14, 2011·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Jianping ZhangSusan J Braunhut
May 4, 2011·Molecular Oncology·Siver Andreas MoestueIngrid Susann Gribbestad
Sep 18, 2012·Biochimica Et Biophysica Acta·Maria Brandal BerstadKristian Berg
Sep 3, 2013·The American Journal of Pathology·Ashley G RivenbarkWilliam B Coleman
Feb 8, 2019·Indian Journal of Clinical Biochemistry : IJCB·Shailendra DwivediPraveen Sharma

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
T SørlieA L Børresen-Dale
International Journal of Cancer. Journal International Du Cancer
Jacques FerlayDonald Maxwell Parkin
Breast Cancer : the Journal of the Japanese Breast Cancer Society
Yutaka TokudaShinobu Umemura
© 2021 Meta ULC. All rights reserved